Genetically modified non-human animal with human or chimeric genes
Genetically modified animals expressing human or chimeric IL12RB1, IL12RB2, and/or IL23R proteins provide a more accurate model for drug screening and evaluation, addressing the limitations of traditional animal models and enhancing drug development efficiency and reducing costs.
Patent Information
- Application Number
- PCT/CN2025/081345
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-01-21
- Filing Date
- 2025-03-07
- Publication Date
- 2025-09-11
AI Technical Summary
Traditional drug research and development methods using in vitro and in vivo animal models fail to accurately replicate human disease states and interactions, leading to high failure rates and increased costs due to the lack of a suitable body environment for drug screening and evaluation.
Development of genetically modified non-human animals expressing human or chimeric IL12RB1, IL12RB2, and/or IL23R proteins, which can be used for drug screening, pharmacodynamics studies, and treatment of immune-related diseases and cancers, providing a more accurate model for human antibody screening and evaluation.
The animal models enhance the efficiency and reduce the cost of drug development by offering a more accurate representation of human disease states and interactions, facilitating the development and design of new drugs and therapies.